President and Chief Medical Officer at Sarah Cannon Research Institute | Advancing Therapies Through Clinical Research #Oncology #Healthcare #CancerResearch
Nashville, TN
- Tweets 124
- Following 752
- Followers 3,100
- Likes 6,110
David R. Spigel, MD, FASCO retweeted
In a recent interview w/ @Blood_Cancers, Dr. Hans Lee of @SCRIOncology discusses how cellular therapies are changing care for patients with advanced multiple myeloma and the importance of expanding access.
Read the Q&A:
The next step in advanced #myeloma is improving access to therapies such as CAR-T and bispecific antibodies, according to Hans Lee, MD, of @SarahCannonDocs.
📖 Read more from this exclusive Q&A: buff.ly/5qX7rQu
4
8
739
David R. Spigel, MD, FASCO retweeted
Breaking from #ASCO26: The Phase 3 #frontMIND trial successfully hit its primary endpoint! 🚨
Adding tafasitamab + lenalidomide to standard R-CHOP significantly improves PFS in newly diagnosed high-risk #DLBCL.
Full story: bit.ly/3REcctU
1
3
401
David R. Spigel, MD, FASCO retweeted
What research is generating buzz heading into #ASCO26? In a new @biospace feature, Dr. @MeredithPelster of Sarah Cannon Research Institute shares insights on promising advances in pancreatic cancer research and targeted therapies.
biospace.com/drug-developmen…
1
4
6
547
David R. Spigel, MD, FASCO retweeted
Inspiring discussion around how we can have greater impact in the community for veterans w/ our colleagues at #FCS & the VA @Dee_Anna_Smith @LucioGordanMD #ASCO26
1
5
305
David R. Spigel, MD, FASCO retweeted
Meet SCRI experts at #ASCO26 for a lymphoma session led by @KrishPatelMD . Join the conversation and learn how we are advancing research for patients.
1
2
182
David R. Spigel, MD, FASCO retweeted
SCRI contributed to research leading to upcoming plenary on Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with met pancreatic adenocarcinoma: Primary analysis from the phase 3 RASolute 302 @MeredithPelster @SCRIOncology #ASCO26
2
6
303
David R. Spigel, MD, FASCO retweeted
Coming up! @MLJohnsonMD2 is coauthor on Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial that will be presented during the Plenary Session at 2:13 p.m. CDT in Hall B1 #ASCO26
3
5
305
David R. Spigel, MD, FASCO retweeted
@SCRIOncology was honored to co-host the @AmericanCancer ACS gala in Nashville.
Amazing fundraising effort benefitting patients facing cancer.
@DavidRSpigel
@MLJohnsonMD2
@MeredithMcKean
@ErikaHamilton9
@BGarmezy
@MeredithPelster
@SPremji7866
@SarahCannonDocs
5
11
1,580
David R. Spigel, MD, FASCO retweeted
🎪 🤡 🐘 🦁
Happy Halloween from the circus!
@MLJohnsonMD2 @DavidRSpigel @VivekSubbiah @BurrisSkip @SarahCannonDocs
1
13
902
David R. Spigel, MD, FASCO retweeted
🚨🚀Pleased to shared with the Universe 👉HOT OFF THE PRESS👉Simultaneously published with the NEW #ESMO25 @myESMO Tumour Agnostic Tack👉 "Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine" @AACR journal @CD_AACR @OncoAlert 👉 Read this paper that will be presented at the special session at ESMO
aacrjournals.org/cancerdisco…
5
25
78
6,703
David R. Spigel, MD, FASCO retweeted
📅 We're counting down until #ESMO25 kicks off in Berlin tomorrow!
🗨️ Don't miss this interview with @StephenVLiu, who discusses anticipated thoracic oncology highlights of the meeting!
➡️ Watch now: buff.ly/mqoXWoA
#lcsm #NSCLC #SCLC #ESMO2025 @myESMO
4
12
965
David R. Spigel, MD, FASCO retweeted
Honored to represent @ASCO and @SarahCannonDocs at the JSCO 2025 conference in Tokyo. We had an amazing conversation about ctDNA in perioperative oncology. I look forward to even more data coming at #ESMO25 #esmo2025
2
1
19
1,375
David R. Spigel, MD, FASCO retweeted
Dr. Hans Lee & Dr. Kris Patel from @SCRIoncology share how new therapies like CAR T-cell treatment are changing lives.
📺 Watch the full @NC5 segment here: piped.video/watch?v=hg4_bwjN…
#BloodCancerAwareness #LymphomaAwareness #CancerCare #SCRI
1
4
683
Congratulations!! Well deserved Stephen!
Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.
1
18
1,201
David R. Spigel, MD, FASCO retweeted
NEW in @OncogeneJournal: @MiNK_iNKT reports complete remission in metastatic, SOC + ICI-refractory testicular cancer with allo-iNKT (agenT-797)
✔️ Durable survival
✔️ No lymphodepletion
✔️ No GVHD
🔗 Builds on 2L gastric PFS + >12mo OS
@Nature nature.com/articles/s41388-0…
3
2
24
872
David R. Spigel, MD, FASCO retweeted
Excited to share a story about the power of clinical trials! Please see our article on oncogene examining a robust and durable response with iNKT cell therapy in a patient with very refractory germ cell tumor.
@SarahCannonDocs and @SCRIOncology
nature.com/articles/s41388-0…
1
2
17
442
Dr. Joyce O’Shaughnessy delivering perfect update in advanced breast cancer research at #MLSNashville #ASCO25 meeting @SarahCannonDocs
2
7
357
David R. Spigel, MD, FASCO retweeted
Happening now at #ASCO25! Dr. Naqash serves as chair during the Oral Abstract Session: Lung Cancer-Non-
Small Cell Local-Regional/ Small Cell/ Other Thoracic Cancers session.
3
19
1,215
David R. Spigel, MD, FASCO retweeted
Happy to present Stellar-002 phase 1b study with zanzalitinib (tki) + nivo or
Nivo/rela. Add to the front line RCC data presented by @JadChahoud. Compelling activity and durability in a pre treated population! #ASCO25 @SarahCannonDocs lots of hard work and thanks to the patients!
1
4
27
1,033
David R. Spigel, MD, FASCO retweeted
Shout out to @ErikaHamilton9 for making sure to pronounce the names of all the speakers in #ASCO25 Plenary Session correctly (and not just the easy ones like “Mark Lewis” @marklewismd😊).
It’s a small thing, but shows respect when you care enough to do it right.
3
8
66
4,236